Sanofi: acquisition of Provention Bio finalized
The tender offer for Provention Bio shares expired on Wednesday evening, and on April 27 Sanofi accepted all shares validly tendered and not withdrawn. Payment for these shares will be made promptly.
Provention Bio shares not tendered to the offer have been converted into a right to receive $25 in cash per share. Effective April 27, all shares of Provention Bio common stock will cease trading on Nasdaq.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction